US firm 22nd Century has begun integration with GVB Biopharma, one of the largest CBD suppliers globally, as part of a plan to grow its hemp/cannabis franchise rapidly.
It exchanged stock worth around $65m for control of the Las Vegas–based CBD company in April. The company added that the aggregate consideration for the transaction consisted of the assumption of approximately $4.5m of debt, GVB’s closing costs, and the issuance to GVB of 32.9m unregistered shares of 22nd Century common stock.
...Are you already a subscriber? login here
Need help?
Contact a sales representative right now and don’t wait
Erik Galavis
+34 654 320 547
Email Erik
Pablo Sharrock
+34 722 642 678
Email Pablo
